The introduction of trastuzumab, a monoclonal antibody targeting the extracellular domain of the human epidermal growth-factor receptor 2 (HER2), revolutionized the treatment of women with HER2+ breast cancer, who were among those with the poorest prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.